NCT07480928 2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT04761770 2026-02-17
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04990323 2025-02-25
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
ExCellThera inc.
Phase 1/2 Recruiting
NCT01516593 2022-08-04
CARMEN
IRCCS San Raffaele
Phase 2 Completed
NCT04395092 2021-06-22
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Kiadis Pharma
Phase 2 Withdrawn
NCT01379209 2019-10-23
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
Phase 1/2 Completed
NCT02053545 2019-08-30
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Withdrawn
NCT02378922 2018-12-27
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT00189488 2014-09-15
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Swedish Orphan Biovitrum
Phase 2 Completed
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown